Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial | Synapse
March 1, 2021Open Access
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
UK Research and Innovation and UK Department of Health and Social Care.